NAGE Niagen Bioscience Inc.
Price (delayed)
$7.08
Market cap
$550.47M
P/E Ratio
64.36
Dividend/share
N/A
EPS
$0.11
Enterprise value
$508.46M
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide
Highlights
NAGE's quick ratio has surged by 85% year-on-year and by 31% since the previous quarter
The equity has surged by 62% year-on-year and by 34% since the previous quarter
Key stats
What are the main financial stats of NAGE
Market
Valuations
Earnings
Shares outstanding
77.75M
Market cap
$550.47M
Enterprise value
$508.46M
Price to earnings (P/E)
64.36
Price to book (P/B)
11.73
Price to sales (P/S)
5.4
EV/EBIT
57.42
EV/EBITDA
49.18
EV/Sales
5.11
Revenue
$99.6M
Gross profit
$61.59M
Operating income
$7.73M
Net income
$8.55M
EBIT
$8.86M
EBITDA
$10.34M
Free cash flow
$11.97M
Per share
Balance sheet
Liquidity
EPS
$0.11
EPS diluted
$0.11
Free cash flow per share
$0.16
Book value per share
$0.6
Revenue per share
$1.31
TBVPS
$0.89
Total assets
$68.28M
Total liabilities
$22.18M
Debt
$2.65M
Equity
$46.09M
Working capital
$46.15M
Debt to equity
0.06
Current ratio
3.57
Quick ratio
2.92
Net debt/EBITDA
-4.06
Margins
Efficiency
Dividend
EBITDA margin
10.4%
Gross margin
61.8%
Net margin
8.6%
Operating margin
7.8%
Return on assets
14.7%
Return on equity
24.4%
Return on invested capital
94%
Return on capital employed
17.6%
Return on sales
8.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NAGE stock price
How has the Niagen Bioscience stock price performed over time
Intraday
3.06%
1 week
-7.45%
1 month
25.53%
1 year
97.21%
YTD
33.46%
QTD
2.61%
Financial performance
How have Niagen Bioscience's revenue and profit performed over time
Revenue
$99.6M
Gross profit
$61.59M
Operating income
$7.73M
Net income
$8.55M
Gross margin
61.8%
Net margin
8.6%
The gross profit has increased by 21% year-on-year and by 9% since the previous quarter
The revenue has grown by 19% YoY and by 9% from the previous quarter
Growth
What is Niagen Bioscience's growth rate over time
Valuation
What is Niagen Bioscience stock price valuation
P/E
64.36
P/B
11.73
P/S
5.4
EV/EBIT
57.42
EV/EBITDA
49.18
EV/Sales
5.11
The equity has surged by 62% year-on-year and by 34% since the previous quarter
NAGE's price to book (P/B) is 39% higher than its last 4 quarters average of 8.2 and 32% higher than its 5-year quarterly average of 8.6
NAGE's price to sales (P/S) is 64% higher than its last 4 quarters average of 3.2 and 42% higher than its 5-year quarterly average of 3.7
The revenue has grown by 19% YoY and by 9% from the previous quarter
Efficiency
How efficient is Niagen Bioscience business performance
Dividends
What is NAGE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NAGE.
Financial health
How did Niagen Bioscience financials performed over time
NAGE's quick ratio has surged by 85% year-on-year and by 31% since the previous quarter
The current ratio has increased by 49% year-on-year and by 21% since the previous quarter
Niagen Bioscience's debt is 94% less than its equity
The equity has surged by 62% year-on-year and by 34% since the previous quarter
NAGE's debt to equity has dropped by 50% year-on-year and by 25% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.